The weekly litigation news digest is live. Subscribe now
The patent EP3874047 was granted to Lonza on Dec 25, 2024. The application was filed on Jan 10, 2020 under application number EP20700131A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".
A method for producing a recombinant protein in a host cell that reduces the risk of cell morphology changes during production. The method involves genetically modifying the host cell to reduce expression of the FLO8 protein, which is involved in cell morphology regulation, and then expressing the recombinant protein under the control of a regulatable promoter that is repressed by a non-methanol carbon source. The modified host cell is cultured under conditions that induce protein production while maintaining cell morphology stability.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent citations refer to prior patents cited during different phases such as opposition or international search.
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents